The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration1

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Immunology

• Publication date

  2005-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4049/jimmunol.174.6.3317PMID 15749863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer vaccines

  2005cited by this paper
• Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization

  2005cited by this paper
• Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee

  2004cited by this paper
• Dendritic cell immunotherapy: mapping the way

  2004cited by this paper
• International Meeting on Cancer Vaccines

  2004cited by this paper
• Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

  2004cited by this paper
• Does the immune system see tumors as foreign or self?

  2003cited by this paper
• Current developments in cancer vaccines and cellular immunotherapy.

  2003cited by this paper
• Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.

  2003cited by this paper
• Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.

  2003cited by this paper
• Cancer vaccines: between the idea and the reality

  2003cited by this paper
• The use of dendritic cells in cancer immunotherapy.

  2003cited by this paper
• Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1

  2003cited by this paper
• Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

  2003cited by this paper
• Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.

  2003cited by this paper
• Adjuvant chemohormonal therapy of high risk prostate carcinoma

  2002cited by this paper
• Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin.

  2002cited by this paper
• Cancer vaccines: progress reveals new complexities.

  2002cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

  2001cited by this paper
• Phenotypic and Functional Analysis of Cd8+ T Cells Undergoing Peripheral Deletion in Response to Cross-Presentation of Self-Antigen

  2001cited by this paper
• Chemotherapy: friend or foe to cancer vaccines?

  2001cited by this paper
• In vivo activation of antigen-specific CD4 T cells.

  2001cited by this paper
• Perforin‐independent regulation of dendritic cell homeostasis by CD8+ T cells in vivo: implications for adaptive immunotherapy

  2001cited by this paper
• Progress in human tumour immunology and immunotherapy

  2001cited by this paper
• Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma1

  2000cited by this paper
• Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.

  2000cited by this paper
• Selective activation and expansion of high-affinity CD4+ T cells in resistant mice upon infection with Leishmania major.

  2000cited by this paper
• Quantitation of CD8+ T-Lymphocyte Responses to Multiple Epitopes from Simian Virus 40 (SV40) Large T Antigen in C57BL/6 Mice Immunized with SV40, SV40 T-Antigen-Transformed Cells, or Vaccinia Virus Recombinants Expressing Full-Length T Antigen or Epitope Minigenes

  2000cited by this paper
• Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.

  2000cited by this paper
• Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness.

  1999cited by this paper
• Pathologic progression of autochthonous prostate cancer in the TRAMP model

  1999cited by this paper
• Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

  1999cited by this paper
• Cancer vaccines

  1998cited by this paper
• Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance.

  1998cited by this paper
• Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• A Natural Immunological Adjuvant Enhances T Cell Clonal Expansion through a CD28-dependent, Interleukin (IL)-2–independent Mechanism

  1998cited by this paper
• Use of adoptive transfer of T‐cell antigen‐receptor‐transgenic T cells for the study of T‐cell activation in vivo

  1997cited by this paper
• In Vivo Detection of Dendritic Cell Antigen Presentation to CD4+ T Cells

  1997cited by this paper
• Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells.

  1997cited by this paper
• Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.

  1996cited by this paper
• Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen

  1995cited by this paper
• Prostate cancer in a transgenic mouse.

  1995influential reference
• Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome

  1995cited by this paper
• Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

  1995cited by this paper
• T cell receptor antagonist peptides induce positive selection.

  1994influential reference
• Severe immunodeficiency in patients treated with fludarabine monophosphate

  1993cited by this paper
• Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

  1991cited by this paper
• Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo.

  1990cited by this paper
• Effects of anticancer drugs on the immune system in humans.

  1989cited by this paper
• The immunoaugmenting effects of cancer chemotherapeutic agents.

  1986cited by this paper
• Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism

  1985cited by this paper
• Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.

  1984cited by this paper
• Regulation of specific cell-mediated cytotoxic response against SV40- induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice

  1979cited by this paper
• The Pharmacological Basis of Therapeutics

  1976cited by this paper
• Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

  1967cited by this paper

• The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells

  2022cites this paper
• A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy.

  2015cites this paper
• Challenges of T-cell therapy

  2014cites this paper
• 8 – Immunology of brain tumors and implications for immunotherapy

  2012cites this paper
• Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

  2012cites this paper
• Redirecting the Immune Response: Role of Adoptive T Cell Therapy

  2010cites this paper
• The Effect of Gefitinib on Immune Response of Human Peripheral Blood Monocyte-Derived Dendritic Cells

  2010cites this paper
• Human myeloid dendritic cells for cancer therapy: does maturation matter?

  2010cites this paper
• Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer.

  2008cites this paper
• Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.

  2008cites this paper
• Anticancer immunotherapy in combination with proapoptotic therapy.

  2008cites this paper
• Vasculature‐targeted tumor necrosis factor‐alpha increases the therapeutic index of doxorubicin against prostate cancer

  2008cites this paper
• A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting

  2008cites this paper
• Tumors Hamper the Immunogenic Competence of CD4+ T Cell-Directed Dendritic Cell Vaccination1

  2007cites this paper
• Vaccine immunotherapy in breast cancer treatment: promising, but still early

  2007cites this paper
• Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer.

  2006cites this paper
• Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer

  2006cites this paper
• Combined chemoimmunotherapy of solid tumours: improving vaccines?

  2006cites this paper
• Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type‐2 cytotoxic T lymphocytes

  2006cites this paper
• Combining cancer vaccines with chemotherapy

  2005cites this paper